Optometry Times

BREAKING: A handful of CRLs issued by the FDA have been announced by their respective companies. Read more on reproxalap: hubs.li/Q0476vch0 Read more on idebenone: hubs.li/Q0476tMq0

BREAKING: Johnson & Johnson announced that the US FDA has approved the TECNIS PureSee IOL, an extended depth of focus lens intended for use in cataract surgery. The lens will be available to patients in the US later this year. Read more: hubs.li/Q046wXBn0

Check out the latest issue of Optometry Times! Read about the convergence of AMD and DED, the new AMD and GA treatment roundup, and the optimization of the ocular surface pre-op, and more. Read the full issue now: hubs.li/Q0450ShW0 #AMD #DryEye #GA #EyeHealth

At the 2026 EnVision Summit, Optometry Times spoke with Rahul S. Tonk, MD, MBA, who provided a forward-looking overview of the rapidly evolving ocular surface landscape. Watch the interview: hubs.li/Q043-kjs0

The competition continues 🥇 Watch the Eye Care Network’s Vision Defenders Inspired by the spirit of the 2026 Olympic Games, this creative spotlight celebrates the clinical leaders shaping our Q1 content. Look for upcoming articles, videos, and podcasts: hubs.li/Q043FZLj0

Julie Pulliam, an optometrist at Washington University in St. Louis who specializes in uveitis and also sees primary care patients, spoke at the EnVision Summit 2026. Watch the interview: hubs.li/Q043GjdS0

An evaluation of commercially available red light devices used to control myopia found that the devices exceeded established safety levels and may damage vision. The recommended duration for red light therapy is 180 seconds. Read more: hubs.li/Q042pgpW0

"Cataract comanagement is often framed around efficiency for both the clinic and the patient; who does what, when referrals happen, and how postoperative visits are divided," writes Cecelia Koetting, OD, FAAO, DipABO. Read more: hubs.li/Q042p5bM0

Sharing a little appreciation this Valentine’s Day for the optometrists who help patients keep sight of what matters most. ❤️ #eyecareprofessionals #optometry #happyvalentinesday

Age-Related Macular Degeneration (AMD) Awareness Month arrives amid a period of notable clinical and regulatory activity that reflects both progress and ongoing challenges in the field. Read more: hubs.li/Q042n_4y0

As pharmacologic options for presbyopia continue to evolve, new therapies are expanding how optometrists approach near-vision correction and patient counseling. Read more: hubs.li/Q042nZYq0

The American College of Physicians (ACP) has published a policy paper arguing that referring to physicians as “providers” carries ethical consequences that extend beyond semantics. Read more and answer our survey: hubs.li/Q042vft20

EnVision Summit 2026 will mark the third year of the conference’s dedicated optometry track, continuing its focus on interdisciplinary education and collaboration between optometrists and ophthalmologists. Read more: hubs.li/Q042p2bp0

Meet the Eye Care Network’s Vision Defenders 🏈 Our Q1 KOLs are bringing sharp clinical insights across glaucoma, retina, nutrition, and practice leadership - introduced with a Super Bowl–inspired twist. Watch who to follow this quarter: hubs.li/Q042bjkW0

An editorial published in the New England Journal of Medicine referred to the Photovoltaic Retina Implant Microarray (PRIMA) Implant as “the first treatment to restore vision” in patients with advanced GA associated with AMD. Read more: hubs.li/Q041y1ws0

"Modern cataract surgery depends on precise preoperative measurements to determine the correct intraocular lens (IOL)," writes Damon Dierker, OD, FAAO. Read more: hubs.li/Q041xCc00

BREAKING: The FDA approval of Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, previously known as Brimochol PF, rings in the first and only dual-agent eye drop for the treatment of presbyopia in adults. Read more: hubs.li/Q040SfgX0

For optometrists, 2026 provides ample opportunity to continue the charge in advancements in dry eye, artificial intelligence (AI), and glaucoma, among other specialties. ODs weighed in on what they predict the new year will bring for eye care. Read more: hubs.li/Q03_t9GM0

Contact lens technology is entering a period of accelerated innovation, reshaping how optometrists address refractive correction, ocular health, and patient lifestyle demands. Read more: hubs.li/Q03_s-sR0

Clinical trial watchers can anticipate the release of data from a number of trials in the first quarter of 2026. The trials focus on Leber hereditary optic neuropathy, dry eye, wet AMD, TED, and meibomian gland dysfunction, among others. Read more: hubs.li/Q03_sV_z0